Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to APT Therapeutics in April, 2017 for $1,902,274.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44HL135993-01 | Phase II | 1,902,274 | April 18, 2017 | |||||||
A SBIR Phase II contract was awarded to APT Therapeutics in September, 2021 for $996,399.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44NS106850-02 | Phase II | 996,399 | September 20, 2021 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2020 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43DK126493-01A1 | Phase I | 300,000 | September 15, 2020 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2019 for $344,933.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43NS113641-01 | Phase I | 344,933 | September 15, 2019 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2018 for $337,602.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HL140699-01A1 | Phase I | 337,602 | September 1, 2018 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2018 for $299,346.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43NS106850-01 | Phase I | 299,346 | September 1, 2018 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in June, 2021 for $259,576.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR079294-01 | Phase I | 259,576 | June 5, 2021 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in April, 2018 for $299,794.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43CA228319-01 | Phase I | 299,794 | April 16, 2018 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2019 for $300,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43CA246779-01 | Phase I | 300,000 | September 18, 2019 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2016 for $225,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AR070662-01A1 | Phase I | 225,000 | September 14, 2016 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2015 for $298,486.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK108315-01 | Phase I | 298,486 | September 20, 2015 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in May, 2016 for $299,200.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK109749-01 | Phase I | 299,200 | May 1, 2016 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2015 for $297,410.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43HL126212-01 | Phase I | 297,410 | September 1, 2015 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in August, 2016 for $2,736,786.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2SB1NS060175-04 | Phase I | 2,736,786 | August 1, 2016 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in September, 2017 for $279,040.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK113815-01 | Phase I | 279,040 | September 15, 2017 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in April, 2017 for $300,437.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44HL135993-01 | Phase I | 300,437 | April 18, 2017 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics in August, 2015 for $299,793.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS093684-01 | Phase I | 299,793 | August 1, 2015 | |||||||
A SBIR Phase II contract was awarded to APT Therapeutics in August, 2016 for $2,999,301.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2SB1NS060175-04 | Phase II | 2,999,301 | August 1, 2016 | |||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $281,598.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43HL115860-01 | Phase I | 281,598 | ||||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $287,622.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS071655-01 | Phase I | 287,622 | ||||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $196,745.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA130192-01A2 | Phase I | 196,745 | ||||||||
A SBIR Phase II contract was awarded to APT Therapeutics for $839,863.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44HL087456-02 | Phase II | 839,863 | ||||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $224,879.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS088993-01 | Phase I | 224,879 | ||||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $187,435.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS060175-01 | Phase I | 187,435 | ||||||||
A SBIR Phase I contract was awarded to APT Therapeutics for $98,750.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43HL076053-01 | Phase I | 98,750 |